'Very good conversations going on' with Iran, says US President Donald Trump

Washington (Web Desk/Agencies): US President Donald Trump said on Saturday that Washington is currently engaged in “very good conversations” with Iran, suggesting that diplomatic engagement is ongoing and producing what he described as positive momentum.

Addressing reporters in the Oval Office, Trump said, “We have very good conversations going on. It's working out very well. They got a little cute, as they have been doing for 47 years. Nobody ever took them on. We took them on,”

He further escalated his remarks while commenting on Iran’s military capabilities, stating, “They have no navy, they have no air force, they have no leaders. They have no nothing. Actually … it is regime change. You call that enforced regime change, but we're talking to them,”

Despite the tough rhetoric, he emphasized that communication channels remain open, saying, “We're talking to them … we're taking a tough stand,” Trump also indicated that developments in the negotiations could be expected soon, adding, “We'll have some information by the end of the day,” while he avoided responding to any further questions about Iran, the ongoing negotiations, or the security situation involving the Strait of Hormuz.

The remarks come against the backdrop of heightened regional tensions following US and Israeli military strikes on Iran that began on February 28. In response, Tehran carried out a series of drone and missile attacks targeting Israel as well as Gulf states hosting American military facilities.

The confrontation was temporarily paused on April 8 after Pakistan facilitated a two-week ceasefire agreement. Subsequent diplomatic engagement followed, with Washington and Tehran holding discussions in Pakistan last weekend, and further rounds of talks being planned in Islamabad.

In a separate development, Trump also signed an executive order aimed at accelerating the approval process for certain psychedelic-based treatments.

He said the directive instructs the US Food and Drug Administration to fast-track evaluation of drugs already classified as breakthrough therapies.

The order is also intended to remove bureaucratic delays, strengthen coordination between the FDA and the Department of Veterans Affairs, and speed up rescheduling procedures once such treatments receive approval.